placebo secukinumab

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Plaque Type PsoriasisSpondylitis, Ankylosing

Phase 3

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

CompletedNCT02008916

Novartis PharmaceuticalsSpondylitis, Ankylosing

Start: 2014-01-14End: 2017-12-11Updated: 2019-01-08

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

CompletedNCT02074982

Novartis PharmaceuticalsChronic Plaque Type Psoriasis

Start: 2014-02-26End: 2016-06-29Updated: 2017-07-21

Related Papers

No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials

Arthritis Research & Therapy2026-04-11

Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.

2022-11-053 citations

Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications

Rheumatology and Therapy2022-03-1933 citations

Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis

Dermatology and Therapy2021-12-067 citations

Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.

2021-11-134 citations

A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis.

2021-10-0712 citations

Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies

The Journal of Rheumatology2021-03-1516 citations

Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.

2020-04-3033 citations

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.

2019-07-2517 citations

Continued treatment with secukinumab is associated with high retention or regain of response.

2019-07-178 citations

Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis

Journal of Dermatological Treatment2019-07-0954 citations

Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

The Journal of Rheumatology2019-06-1529 citations

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.

2017-12-22159 citations

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.

2015-06-17394 citations